How to Sequence Therapies in Mycosis Fungoides

• Published in: Current treatment options in oncology Vol. 22; no. 11; p. 101
• Main Authors: Brumfiel, Caitlin M., Patel, Meera H., Puri, Pranav, Besch-Stokes, Jake, Lester, Scott, Rule, William G., Khera, Nandita, Sluzevich, Jason C., DiCaudo, David J., Comfere, Nneka, Bennani, N. Nora, Rosenthal, Allison C., Pittelkow, Mark R., Mangold, Aaron R.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.11.2021; Springer Nature B.V
• Subjects: Biomarkers, Tumor; Clinical Decision-Making; Combined Modality Therapy - adverse effects; Combined Modality Therapy - methods; Disease Management; Disease Susceptibility; Fungal infections; Humans; Immunosuppressive agents; Lymphoma; Lymphoma (JL Muñoz; Medicine; Medicine & Public Health; Mycosis; Mycosis fungoides; Mycosis Fungoides - diagnosis; Mycosis Fungoides - etiology; Mycosis Fungoides - therapy; Neoplasm Grading; Neoplasm Staging; Oncology; Quality of life; Section Editor; Skin Neoplasms - diagnosis; Skin Neoplasms - etiology; Skin Neoplasms - therapy; Topical Collection on Lymphoma; Treatment Outcome; Mycosis fungoides; Cutaneous oncology; Cutaneous T cell lymphoma; CTCL; Lymphoma
• ISSN: 1527-2729; 1534-6277; 1534-5277
• DOI: 10.1007/s11864-021-00899-0

Opinion statement Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.